Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine

NCT04090034 is registered in ClinicalTrials.gov with Methodist Health System as lead sponsor.

NCT NCT04090034
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04090034 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine
Lead sponsor
Methodist Health System
Phase
Observational
Overall status
Recruiting
Start date
March 28, 2024
Completion date
June 28, 2026
Enrollment
50 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

gastroenteropancreatic neuroendocrine tumor, neuroendocrine tumors